Sarcoma of the corpus uteri

Sarcoma of the corpus uteri is a rare and aggressive malignant tumor arising from the mesenchymal (connective) tissues of the uterine body. Unlike the more common endometrial carcinomas, which originate from the glandular lining of the uterus, uterine sarcomas develop from the smooth muscle, stromal, or other supportive tissues of the uterine wall. The major subtypes include uterine leiomyosarcoma (arising from smooth muscle), endometrial stromal sarcoma (arising from the uterine stroma), and undifferentiated uterine sarcoma. These tumors collectively account for a small percentage of all uterine malignancies but carry a disproportionately poor prognosis compared to endometrial carcinomas. Key symptoms include abnormal uterine bleeding (the most common presenting symptom), a rapidly enlarging pelvic mass, pelvic pain or pressure, and occasionally vaginal discharge. Some patients may present with symptoms related to metastatic disease, as uterine sarcomas have a tendency for early hematogenous spread, particularly to the lungs. The disease primarily affects the reproductive system but can metastasize to the lungs, liver, bones, and peritoneal cavity. Treatment typically involves surgical intervention, with total hysterectomy and bilateral salpingo-oophorectomy being the standard primary approach. The role of lymph node dissection varies by subtype. Adjuvant therapy options include chemotherapy (commonly doxorubicin-based regimens or gemcitabine-docetaxel combinations, particularly for leiomyosarcoma) and radiation therapy, though their benefit in improving overall survival remains debated and is often subtype-dependent. Hormonal therapy may be considered for low-grade endometrial stromal sarcomas, which frequently express hormone receptors. Prognosis depends heavily on the histological subtype, tumor stage at diagnosis, and the completeness of surgical resection. Overall, uterine sarcomas remain challenging to treat, and clinical trials investigating targeted therapies and immunotherapy are ongoing.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Sarcoma of the corpus uteri